Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · December 15, 2021

Safety and Efficacy of Tocilizumab in Patients With Early Systemic Sclerosis–Interstitial Lung Disease

American Journal of Respiratory and Critical Care Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

American Journal of Respiratory and Critical Care Medicine
Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open Label Extension of a Phase 3 Randomized Controlled Trial
Am J Respir Crit Care Med 2021 Dec 01;[EPub Ahead of Print], D Khanna, CJF Lin, DE Furst, B Wagner, M Zucchetto, G Raghu, FJ Martinez, J Goldin, J Siegel, CP Denton

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading